Harrow Health Inc
NASDAQ:HROW
Net Margin
Harrow Health Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Harrow Health Inc
NASDAQ:HROW
|
1.2B USD |
-10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.5B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
405B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.6B CHF |
14%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
35%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
178.2B GBP |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
184.4B CHF |
25%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
209.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.5B USD |
13%
|
Harrow Health Inc
Glance View
Nestled within the bustling world of pharmaceutical innovation, Harrow Health Inc. emerges as a dynamic player with a distinctive business model tailored to transforming ophthalmic healthcare. With its roots planted firmly in the field of eye care, Harrow Health has mastered the art of compounding pharmaceuticals, focusing on delivering affordability and accessibility. The company operates primarily through its subsidiary, ImprimisRx, a compounding pharmacy that serves a robust network of ophthalmologists and optometrists across the United States. ImprimisRx’s unique approach involves creating custom-formulated medications tailored to specific patient needs, often at prices more competitive than traditional offerings. By prioritizing the compounding of prescription medications in its expansive network of accredited pharmacies, Harrow Health crafts a niche in the high-demand ophthalmology sector. Central to Harrow Health’s business strategy is its ability to capitalize on inefficiencies in the traditional drug market. By emphasizing a direct-to-prescriber model, the company circumvents many of the traditional barriers and costs associated with large pharmaceutical firms. This allows for a reduction in drug prices and improves distribution efficiency. Moreover, Harrow Health’s focus extends beyond compounding; it is actively involved in acquiring and licensing innovative ophthalmic technologies and products, constituting a broader ecosystem within eye care. This multi-pronged approach not only drives revenue through direct sales but also strengthens its position in the healthcare sector by investing in emerging therapies and expanding its reach in the marketplace. Such strategic maneuvers allow Harrow Health to sustain its growth trajectory while continuing to champion patient-centered care.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Harrow Health Inc's most recent financial statements, the company has Net Margin of -10.2%.
You don't have any saved screeners yet